Lonza will initially manufacture clinical trial batches of five compounds currently in Phase 1 and 2 for GSK, it said. The group did not give any financial details of the deal.
The Basel-based group, which has moved away from specialty chemicals to focus on higher-margin pharmaceutical ingredients, had said its business was set to recover further as clients from the pharmaceuticals industry placed more orders.
Lonza has been hit by drugmakers cutting their inventories during the downturn and has reacted by cutting costs.
Faced with a tougher road to get their medicines to market, some drugmakers are becoming increasingly cost conscious and prefer to keep some manufacturing in-house rather than turning to companies like Lonza.
(Reporting by Sven Egenter; Editing by Karen Foster)
(c) Reuters 2012. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
